Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update
Topline results from the PROSERA Study are expected in the fourth quarter of 2025.
- Topline results from the PROSERA Study are expected in the fourth quarter of 2025.
- On May 6, Gossamer Bio and Chiesi Group announced a development and co-commercialization collaboration for seralutinib.
- Gossamer and Chiesi will split global development costs for seralutinib, except for the PROSERA Study, for which Gossamer will remain solely responsible.
- Financial Results for Quarter Ended March 31, 2024
Cash, Cash Equivalents and Marketable Securities: Cash, cash equivalents and marketable securities as of March 31, 2024, were $244.4 million.